C4 Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
0.9%projected annual EPS growth
Analyst Coverage
6analysts covering
FY EPS (est.)
-$0.96next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 9 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents and Marketable Securities Quarterly268.3MTarget: Sufficient to fund operations to the end of 2028
Cemsidomide (CFT7455) Phase 2 MOMENTUM Trial Enrollment QuarterlyTarget: Complete enrollment by the first quarter of 2027
Quarterly Collaboration Revenue Quarterly6.2M
Watch Items
- Cemsidomide (CFT7455) Phase 2 MOMENTUM Trial Efficacy and Safety DataTrigger: Initial data expected in H2 2027; regulatory endpoints in mid-2028Action: Evaluate clinical proof-of-concept and potential registrational pathways for relapsed/refractory multiple myeloma
- Phase 1b Combination Trial of Cemsidomide with ElranatamabTrigger: Full data anticipated mid-2027Action: Assess safety, tolerability, and early efficacy in earlier lines of multiple myeloma treatment
- Roche Degrader-Antibody Conjugate (DAC) Collaboration ProgressTrigger: Receipt of $20 million upfront payment in May 2026Action: Monitor research milestones and development candidate nominations under the expanded partnership
Research as of 20 Jun 2026